Drug intelligence / Profile preview

H001

Development stage: Phase 2
Lead developer: Livzon Pharmaceutical
Administration: Oral

Overview

H001 is an investigational drug developed by Livzon Pharmaceutical Group. It is being studied in clinical trials as an oral capsule formulation for the **prevention of venous thromboembolism (VTE)** following knee arthroplasty (knee replacement surgery). As of the latest reports, H001 is in Phase II clinical development[3][7]. Specific details about its **mechanism of action**, molecular class, and drug target have not been publicly disclosed in available sources.

Beyond the preview

Go deeper on H001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on H001.

Explore the full profile